Human melanoma cell lines, SK-MEL-3 and SK-MEL-28, despite induction of the proapoptotic cytokine, Apo2L/TRAIL, did not undergo apoptosis in response to interferons . Postulating that genes important for apoptosis induction by IFNs might be silenced by methylation, the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5-AZAdC) was assessed. DR4 (TRAIL-R1) was identified as one of the genes reactivated by 5-AZAdC with a >3-fold increase in 8 of 10 melanoma cell lines. Pretreatment with 5-AZAdC sensitized SK-MEL-3 and SK-MEL-28 cells to apoptosis induced by IFN-a2b and IFN-b; methylation-specific PCR and bisulfite sequencing confirmed demethylation of 5 0 CpG islands of DR4 and flow cytometry showed an increase in DR4 protein on the cell surface. In cells with reactivated DR4, neutralizing mAB to TRAIL reduced apoptosis in response to IFN-b or Apo2L/TRAIL. To further confirm the role of DR4, it was expressed by retroviral vector in SK-MEL-3 and SK-MEL-28 cells with reversal of resistance to IFN-b and Apo2L/TRAIL. Thus, reexpressing DR4 by 5-AZAdC or retroviral transfection in melanoma cell in which promoter methylation had suppressed its expression, potentiated apoptosis by IFNa2b, IFN-b and Apo2L/TRAIL. Reactivation of silenced proapoptotic genes by inhibitors of DNA methylation may enhance clinical response to IFNs or Apo2L/TRAIL.
Introduction
Interferons (IFNs) play a critical role in host response to cancer through innate immune response and direct effects on cancer cells resulting in tumor cell death or differentiation and inhibition of angiogenesis (Pfeffer et al., 1998; Stark et al., 1998; Borden, 2003) . Biological effects of IFNs result from transcriptional regulation of a subset of genes, called IFN-stimulated genes (ISGs). Gene microarray studies have identified >300 induced ISGs in fibrosarcoma or in melanoma cells treated with IFNs (Der et al., 1998; Leaman et al., 2003) . ISG products implicated as contributing to IFN-induced apoptosis include Apo2L/TRAIL, FasL, XAF1, protein kinase R, death-associated protein kinase, IRF1, RNaseL and 2-5 OA synthetase . Resistance of cells to IFNs has been related not only to defects in specific components of the signaling cascade but also to homeostatic mechanisms that modulate receptor activation and transcriptional response.
Epigenetic silencing by aberrant hypermethylation in the promoter region of tumor suppressor genes likely contributes to the development of cancers including melanomas (Herman and Baylin, 2003; Egger et al., 2004; Hoon et al., 2004) . Gene expression profiling has identified genes involved in IFN pathways that are epigenetically silenced by hypermethylation of their 5 0 regulatory CpG islands (Lu et al., 2000; Esteller et al., 2001; Byun et al., 2003) . As a nucleoside analogue, 5-aza-2 0 -deoxycytidine (5-AZAdC) incorporates into DNA and covalently binds DNA methyltransferase l (DNMT1), thus inhibiting maintenance of DNA methylation and resulting in reexpression of epigenetically silenced genes (Herman and Baylin, 2003) . Treatment of spontaneously immortal Li-Fraumeni fibroblasts with 5-AZAdC reactivated expression of 85 genes, 46% of which were ISGs (Kulaeva et al., 2003) . Few studies, however, have examined functional consequences of epigenetic silencing of protein products of ISGs or their interacting ligands.
We hypothesized that 5-AZAdC-mediated reactivation of epigenetically silenced genes might sensitize melanoma cells to apoptosis induced by IFNs. Melanoma cell lines resistant to apoptosis induction by either IFN-a2b or IFN-b were evaluated for increase in gene expression by 5-AZAdC. DR4, a receptor for Apo2L/ TRAIL, was identified as an epigenetically silenced gene with a critical role in apoptosis induced by IFN-a2b, IFN-b and Apo2L/TRAIL.
Results
Effect of 5-AZAdC on DNMT1 protein and IFN-a2b-and IFN-b-induced apoptosis To examine inhibition of DNMT1 by 5-AZAdC on melanoma cell lines, SK-MEL-3 and SK-MEL-28 were treated every day for 4 days with 0.1, 0.2 and 0.5 mM of 5-AZAdC. In both cell lines DNMT1 protein in whole cell lysates was markedly reduced by even 0.1 mM of 5-AZAdC over 96 h (Figure 1a) .
To investigate whether 5-AZAdC overcame resistance of melanoma cells to IFN-induced apoptosis, terminal transferase dUTP nick end labeling (TUNEL) assay was undertaken. Both of these cell lines were resistant to IFN-a2b or IFN-b-induced apoptosis (o5% TUNELpositive cells) at the highest doses of IFNs (1500 U/ml) tested (data not shown). Similarly, 5-AZAdC (0.1 mM over 96 h) caused little apoptosis (o10% TUNELpositive cells). However, pretreatment with 5-AZAdC sensitized these cells to IFN-a2b or IFN-b-induced apoptosis (13-70% TUNEL-positive cells) at 100 IU/ml ( Figure 1b ). Compared to IFN-a2b, IFN-b was more potent in inducing apoptosis (Figure 1b) . Apoptosis induction was confirmed by caspase 3 cleavage using immunoblotting. Treatment with IFN-a2b or IFN-b after 5-AZAdC resulted in strong caspase 3 cleavage when compared to 5-AZAdC or IFNs alone (Figure 1c) . Thus, 5-AZAdC potentiated apoptosis activity of IFNs at relatively low concentrations in otherwise resistant melanoma cells.
Induction of IFN-related genes by 5-AZAdC
To determine if DNMT1 inhibition by 5-AZAdC leads to expression of genes related to signaling or apoptosis, quantitative real-time reverse transcription (qRT)-PCR was performed on RNA extracted from SK-MEL-3 and SK-MEL-28 cells treated with 0.1 mM of 5-AZAdC for 96 h. Since IFNs induce Apo2L/TRAIL expression, a potent inducer of apoptosis, genes in the Apo2L/TRAIL pathway and other proapoptotic genes (IRF1, STAT1 and STAT2, Fas and XAF1) were examined (Table 1) . Among the nine genes, expression of DR4 (TRAIL R1) was the only gene markedly increased by 5-AZAdC in both cell lines (Table 1) . DR4 expression increased 29-fold in SK-MEL-28 and 74-fold in SK-MEL-3 cells. Expression of Apo2L/TRAIL, DR5 and XAF1 was increased after 5-AZAdC (>3 Â ) in one or both cell lines. Neither STAT1 nor STAT2 was increased by 5-AZAdC. IFN-b (100 IU/ml for 16 h) markedly induced TRAIL and XAF1 and to a lesser extent STAT1 and STAT2 in both cell lines (Table 1) . Thus, strong augmentation of DR4 expression resulted from the inhibition of DNA methylation by 5-AZAdC, while IFN-b induced TRAIL in both cell lines.
To determine whether DR4 mRNA expression induced by 5-AZAdC was limited to SK-MEL-3 and SK-MEL-28 cell lines or was a more general phenomenon in melanomas, a panel of eight additional melanoma cell lines was evaluated. In 8 out of 10 cell lines including SK-MEL-3 and SK-MEL-28, 5-AZAdC increased the expression of DR4 by >3-fold (Supplementary Figure 1 ).
Methylation status of DR4 in melanoma cell lines
To investigate whether induction of DR4 by 5-AZAdC resulted from demethylation of the promoter of DR4, methylation-specific PCR (MSP) was undertaken using specific primers that recognize CG sites near transcription start sites. As a DR4 unmethylated control, ACHN renal cancer cells were used. SK-MEL-28 cells had a methylated 5 0 regulatory CpG island that was partially demethylated by 5-AZAdC treatment (0.1 mM over 96 h) ( Figure 2a ). For confirmation of DR4 demethylation, bisulfite sequencing was undertaken after cloning of hemi-nested PCR products. Eighteen CpG sites between À27 and À264 nt from the transcription start site were investigated. In SK-MEL-28 cells 14-17 CG sites were methylated and 5-AZAdC demethylated CpG sites close to the transcription start site (Figure 2b ). 
Role of TRAIL in sensitization to IFNs by 5-AZAdC
Since IFN-b markedly increased Apo2L/TRAIL RNA (Table 1) , enzyme-linked immunosorbent assay (ELISA) was performed to measure the concentration of Apo2L/ TRAIL in cell culture supernates and as combined totals of culture supernates and cell extracts (Table 2 ). Apo2L/ TRAIL was not detected with 5-AZAdC treatment alone at any time point. IFN-b increased Apo2L/ TRAIL protein levels in supernates by 24 h (51 pg/ml), an effect that was further increased at 48 and 72 h. IFNa2b also increased Apo2L/TRAIL expression, but to a lesser extent. In cells pretreated with 5-AZAdC, IFNs had an augmented Apo2L/TRAIL expression (442 pg/ml at 24 h) ( Table 2) .
Since IFN-b-induced Apo2L/TRAIL is the natural ligand for DR4, its role in 5-AZAdC plus IFN-binduced apoptosis was assessed using an Apo2L/TRAIL neutralizing antibody. Like IFN-b, treatment of SK-MEL-28 cells with Apo2L/TRAIL (200 ng/ml) did not result in any marked increase in apoptosis (Figure 5a ). However, 5-AZAdC pretreatment sensitized these cells to Apo2L/TRAIL and increased the apoptosis percentage (3.8-38.9%) (Figure 5b) . Similarly, 5-AZAdC plus IFN-b combination resulted in 24.4% of apoptosis. (Tables 1 and 2 ), these cells were resistant to apoptosis (o5% TUNELpositive cells). However, when these and other IFN-a2b, IFN-b or TRAIL-resistant melanoma cells were pretreated with 5-AZADC, they became sensitive to these cytokines, suggesting that 5-AZAdC treatment restored a critical element(s) of Apo2L/TRAIL signaling pathways. Under these conditions, 5-AZAdC depleted available DNMT1 protein in SK-MEL-28 cells resulting in DNA hypomethylation and reactivation of methylation-silenced genes (Figure 2) . Semiquantitative measurement of the expression of critical genes in Apo2L/ TRAIL and IFNs signaling pathways identified DR4, a receptor of Apo2L/TRAIL, as being reexpressed by 5-AZAdC.
Apo2L/TRAIL mediates apoptosis through interaction with two receptors, DR4 and DR5 (Ashkenazi and Dixit, 1998) . TRAIL-activated DR4 and DR5 receptors can initiate apoptotic signals by activation of procaspase 8 resulting in activation of downstream effector caspases In SK-MEL-28 cells, 5-AZAdC partially reversed hypermethylation of CpG islands in the DR4 promoter region close to transcription start sites (Figures 2a and  b) and correspondingly DR4 mRNA levels (Table 1) , and DR4 protein expression on the cell membrane was increased (Figure 3) . Additionally, 5-AZAdC markedly increased (>3 Â ) the expression of DR4 in 8 out of 10 melanoma cell lines tested (Supplementary Figure 1) . In contrast DR5 (TRAIL R2) RNA was increased in only 4 out of 10 melanoma cell lines (Supplementary Figure  1) , suggesting that DR4 might be more frequently silenced by methylation in melanomas. 5-AZAdC followed by IFN-b further increased cell surface expression of DR4 in both SK-MEL-3 and SK-MEL-28 cells whereas IFN-a2b increased DR4 expression only in SK-MEL-28 cells (Figure 3 ). Both 5-AZAdC and IFN-b have pleotropic effects on gene expression. Thus, DR4 was ectopically expressed in SK-MEL-3 and SK-MEL-28 cells to specifically assess its direct contribution to apoptosis mediation by IFN-a2b or IFN-b (Figure 4b ). Overexpression of DR4 restored sensitivity of both of these cell lines to IFN-b and Apo2L/TRAIL whereas IFN-a2b had a marginal effect in inducing apoptosis in SK-MEL-28 cells. In a corollary experiment, Apo2L/TRAIL neutralizing antibody inhibited apoptosis in 5-AZAdC pretreated cells exposed to IFNb (Figure 4 ). These findings thus identified epigenetic silencing of DR4 as a mechanism of resistance to IFN-binduced apoptosis that can be overcome by DNAdemethylating agents. Additionally IFN-b-induced Apo2L/TRAIL was necessary for this process.
We cannot eliminate a contribution of nonspecific cellular effects of 5-AZAdC that extend beyond covalent binding of DNMTs and thus might result in off-target effects. However, the concentrations of 5-AZAdC used alone resulted in marked reduction of DNMT1 ( Figure 1a ) and little or no apoptosis (Figures 1b and c) . A model for augmentation of IFN-b-mediated apoptosis by 5-AZAdC would require both demethylation and reactivation of DR4 and increased expression of Apo2L/TRAIL for efficient apoptosis induction ( Figure 6 ).
Other proapoptotic gene products may have contributed to apoptosis induction by the combination of 5-AZAdC and IFNs. Real-time RT-PCR (Table 1) and immunoblotting (data not shown) also identified cellspecific induction of XAF1 by IFNs, markedly in SK-MEL-28 but less in SK-MEL-3. XAF1 interacts with an inhibitor of apoptosis (XIAP) that may function as a competitive inhibitor of caspases to play a critical role in TRAIL-induced apoptosis (Deveraux et al., 1997; Liston et al., 2001; Leaman et al., 2002; Chawla-Sarkar et al., 2004) . XAF1 has been silenced by DNA methylation in gastric cancer and is frequently reduced in expression in melanoma (Byun et al., 2003; Ng et al., 2004; Reu et al., 2006a) . However, in SK-MEL-3 and SK-MEL-28 cells, 5-AZAdC had a marginal effect on XAF1 mRNA expression (Table 1 ). The tumor suppressor RAS association domain family protein 1 (RASSF1A) was also induced by 5-AZAdC in SK-MEL-28 cells but not in SK-MEL-3 cells (data not shown). Silencing of RASSF1A by methylation of its promoter region has been identified as a frequent change in malignant melanomas and in renal carcinoma cells (Spugnardi et al., 2003; Reu et al., 2006b ).
In conclusion, reactivation of DR4 expression by reversal of promoter-specific methylation in DNA by inhibitors such as 5-AZAdC contributed to overcoming resistance of two melanoma cell lines to apoptosis induced by IFN-b or Apo2L/TRAIL. Without reversal of epigenetic gene silencing, cells studied were resistant to apoptosis induction by both TRAIL and IFNs. Inhibition of aberrant methylation of promoters of proapoptotic genes could enhance sensitivity of melanoma and other cancers to IFNs, Apo2L/TRAIL or other apoptosis-inducing molecules.
Materials and methods

Cell lines and reagents
Human melanoma cell lines were purchased from the ATCC and propagated in recommended media.
IFN-a2b (Intron A, Schering-Plough Inc., Kenilworth, NJ, USA; specific activity 2 Â 10 8 U/mg protein), IFN-b (Rebif, Serono Inc., Geneva, Switzerland; specific activity 2 Â 10 8 U/ mg protein), TRAIL (PeproTech Inc., Rocky Hill, NJ, USA) and 5-AZAdC (Sigma Chemical Co., St Louis, MO, USA) were used at indicated concentrations. 0  35  51  34  66  169  442  48  0  0  43  53  30  56  170  264  72  14  14  102  112  32  57  132  193 Abbreviations: 5-AZAdC, 5-aza-2 0 -deoxycytidine; IFN, interferon. SK-MEL-28 cells (1 Â 10 6 cells) were treated with 500 IU/ml of IFNa2b or IFN-b after 0.1 mM of 5-AZAdC over 4 days. At 24, 48 and 72 h after addition of IFNs, Apo2L/TRAIL ELISA was carried out using concentrated conditioned media and cell lysates. 
Western blot
Whole cell extracts (WCE) were made and 30 mg of WCE was subjected to immunoblot analysis as described (Reu et al., 2006a, b) . Polyclonal DNMT1 (kindly provided by MethylGene, Quebec, Canada) and caspase 3 (BioMol, Plymouth Meeting, PA, USA) antibodies were used at 1:5000 and 1:3000, respectively. Membranes were reprobed with an actin monoclonal antibody (Sigma Chemical Co.) to assess equal loading of samples.
TUNEL assay TUNEL assay was performed using Apo-BrdU kit (BD PharMingen, San Diego, CA, USA) according to the manufacturer's instructions.
Quantitative real-time PCR Quantitative real-time RT-PCR was performed using primer pairs and reaction mixtures from Applied Biosystems (Foster City, CA, USA) using an ABI 7500 (Applied Biosystems) as described (Reu et al., 2006a, b) .
ELISA assay for Apo2L/TRAIL SK-MEL-28 cells were treated with 0.1 mM of 5-AZAdC over 96 h, then 1 Â 10 6 cells were replated per 10 cm dish and treated with 500 IU/ml of IFN-a2b or IFN-b. For examination of induction or secretion of Apo2L/TRAIL, conditioned media was collected at 24, 48 and 72 h after the addition of IFNs and concentrated using Vivaspin15 (Vivascience, Hannover, Germany) filters. Cell lysates were prepared using lysis buffer (R&D Systems, Minneapolis, MN, USA) and Apo2L/TRAIL concentrations in conditioned media or in lysates were measured by ELISA according to the manufacturer's instructions.
Methylation-specific PCR and bisulfite sequencing for DR4 Bisulfite modification and MSP were performed as described previously (Reu et al., 2006a, b) . Specific primers were designed to detect unmethylated (U) or methylated (M) CG sites within CpG islands near the transcription start site. The primer sequences for MSP of DR4 were U sense 5 0 -CCCCTTTTCAAAACACCTACA-3 0 and U antisense 5 0 -GAAAGGTTGAGGTTAATTTTTGATT-3 0 , M sense 5 0 -CC TTTTCGAAACACCTACGAC-3 0 and M antisense 5 0 -AAA GGTTGAGGTTAATTTTCGATC-3 0 . For bisulfite sequencing, hemi-nested primers were designed to cover 18 CG sites from À15 to À269 nt 5 0 of the transcription start site, sense1 5 0 -GGGTGTTAGGAATT GGGTTATAGA-3 0 , sense2 5 0 -TTGGGTTATAGAAAGGTT GAGGTTA-3 0 and antisense 5 0 -ATCCTACCAAATCAATC CAAAAAA-3 0 . Hemi-nested PCR reaction for DR4 sequencing was carried out for five cycles at 941C for 60 s, 571C for 120 s, 721C for 90 s, and then for 25 cycles at 941C for 60 s, 571C for 90 s, 721C for 90 s with extension at 721C for 10 min. The amplified DNA was cloned into a TA cloning vector (Invitrogen, Carlsbad, CA, USA). Ten colonies were picked and digested using EcoR1 (Fisher, Pittsburgh, PA, USA) for sequencing using an ABI 7700 Sequencer (Applied Biosystems).
Staining of cell surface DR4
For detection of cell surface DR4, cells were harvested using versene (Invitrogen), washed with cold phosphate-buffered saline and incubated with DR4 antibody (Imgenex, San Diego, CA, USA) for 45 min on ice. Fluorescein isothiocyanate (FITC)-conjugated anti-mouse immunoglobulin G was used as secondary antibody (BD PharMingen) and analysed by flow cytometry.
Neutralization of Apo2L/TRAIL Cells were treated with IFN-b or Apo2L/TRAIL and concurrently with Apo2L/TRAIL neutralizing antibody or control antibody (Prosci, Poway, CA, USA) at 3 mg/ml for 48 h.
Retroviral transduction and ectopic expression of DR4
Retroviral expression vector containing FLAG-DR4 was made by subcloning CMV-FLAG-DR4 from pCMV-FLAG-DR4 (a kind gift from Thomas Griffith) into pQCXIP (Clontech Laboratories, CA, USA) at Xba1-BamH1 sites. The pantropic virions were produced in GP293 cells using Calphos Mammalian Transfection kit (Clontech Laboratories) according to manufacturer's protocol. Both SK-MEL-3 and SK-MEL-28 cells were transduced with either vector or DR4 virions and were selected in puromycin (1 mg/ml) for 4 days. Drug-resistant clones were replated in a six-well plate at 3 Â 10 5 cells/well to assess sensitivity to IFN-a2b, IFN-b or Apo2L/TRAIL and DR4 expression.
